EuroChem

EuroChem-VolgaKaliy

 

The Gremyachinskoe potash project is a top priority for EuroChem and we currently expect to produce our first potash in 2014, ramping up to full capacity for phase I of 2.3 mmt p.a. by 2015.  With the help of this and other potash investments, EuroChem plans to become a top-5 global fertilizer producer, and one of only three companies worldwide that produces fertilizers in all three of the primary nutrient groups (N, P and K).  Some of the competitive advantages of the Gremyachinskoe project are:

  • Higher nutrient content of ore
  • New mines and processing plant will be more efficient and require less personnel than legacy facilities
  • Proximity to EuroChem’s Tuapse bulk terminal (approx. 500km)

 

License details
License area: 96.9 km2 located in Volgograd region
Depth: 1,000–1,250 meters
License acquired 2005, via auction process
Purchase price US$ 106m (RUB 3.087bn)
Reserves and resources
Russian classification (per Minutes of GKZ as № 2339 of 26.11.2010) m tonnes
Reserves (B+C1+C2) 1,613
Off-balance reserves (С1+С2) 0,074
   
JORC (per independent appraisal’s report as of September 2009) m tonnes
Proven and Probable reserves 492
Measured and Indicated resources 1,337
Nutrient content of Sylvinite ore
KCl average content 39,5%
NaCl average content 54%
MgCl average content 0.2%
CaSO4 average content 6-7%
Development and Production

Phase I:

  • Capacity of 2.3 mmt p.a.
  • Production to start in 2014, full capacity to be reached in 2015
  • Involves construction of social and logistics infrastructure, cage and skip shafts, and new processing plant
  • Total investment estimated at US$ 2.3bn

Phase II:

  • Additional capacity of 2.3 mmt p.a. (total capacity doubled to 4.6 mmt p.a.)
  • Involves construction of additional skip shaft and expansion of existing processing plant capacity
  • Production to start in 2015, full capacity to be reached in 2018
  • Total investment estimated at US$ 1.1bn

Phase I plus Phase II:

  • Total capacity of 4.6 mmt p.a.
  • Total investment estimated at US$ 3.4bn